Blastic plasmacytoid dendritic cell neoplasm:Two case reports  

作　　者：Yi-Qian Ma Zhan Sun Yu-Mei Li Hui Xu 

机构地区：[1]Department of Dermatology,The Affiliated Hospital of Jiangsu University,Zhenjiang 212000,Jiangsu Province,China

出　　处：《World Journal of Clinical Oncology》2024年第9期1207-1214,共8页世界临床肿瘤学杂志（英文版）

基　　金：Supported by The National Key Research and Development Programs of China,No.2022YFC2603801;Maternal and Child Health Project of Jiangsu Province,No.F201717;Doctor Project of Affiliated Hospital of Jiangsu University,No.jdfyrc2019003;Clinical and Virology Study of 2019-ncov Infection in Patients with Moderate to Severe Psoriasis,No.Jdfyxgzx005.

摘　　要：BACKGROUND Blastic plasmacytoid dendritic cell tumor(BPDCN)is a rare and highly invasive lymphohematopoietic tumor that originates from plasmacytoid dendritic cells.BPDCN has an extremely poor prognosis.Skin lesions are usually the first manifestation of BPDCN,although the tumor may also invade the bone marrow,lymph nodes,peripheral blood,and other parts of the body,leading to several other manifestations,requiring further differentiation through skin biopsy and immunohistochemistry.CASE SUMMARY In the present paper,the cases of 2 patients diagnosed with BPDCN are discussed.The immunohistochemistry analysis of these 2 patients revealed positivity for CD4,CD56,and CD123.Currently,no standard chemotherapy regimen is available for BPDCN.Therefore,intensive therapy for acute lymphoblastic leukemia was applied as the treatment method for these 2 cases.CONCLUSION Although allogeneic bone marrow transplantation could be further effective in prolonging the median survival the ultimate prognosis was unfavorable.Future treatment modalities tailored for elderly patients will help prolong survival.

关 键 词：Blastic plasmacytoid dendritic cell neoplasm SKIN CD4 CD56 CD123 Venetoclax Case report 

分 类 号：R739.62[医药卫生—肿瘤]